Navigation Links
EORTC at 2013 ECCO-ESMO-ESTRO meeting in Amsterdam
Date:9/13/2013

The EORTC will have an active presence at the 2013 ECCO-ESMO-ESTRO Meeting in Amsterdam, The Netherlands, from 27 September to 01 October 2013 and would like to call your attention to the following presentations.

Society Session

F. Meunier and R. Stupp are co-Chairs of the session "European Organisation for Research and Treatment of Cancer (EORTC) - Multidisciplinary Cancer Clinical Research: What are we up to in 2013?" on Saturday, 28 September 2013 from 16:00 - 18:00 in Room G102.

Special sessions

J. Bogaerts will chair a Special session, "Dilemma of Crossover in Clinical Trial Design of Agents with 'Obvious Activity'" On Saturday, 28 September 2013 from 14:15 15:15 in Elicium 1. During this session he will also present "Cross over in oncology trials: Considerations for endpoints and trial design - arguments pro and contra".

S. Litire will present "Data warehouse and uncertainties in response measurements" in a special session on Tumor Response Assessment on Sunday, 29 September at 13:25 in Room E102.

Debates

F. Meunier will speak in favor during the Regulatory/Trial Methodology/Pharmacy debate, "This House Believes That the EU Clinical Trials Directive has Harmed European Clinical Studies" on Monday, 30 September 2013 from 17:00 18:00 in Room D201.

L. Collette will present as a seconder against in a debate entitled "This House Believes That New Technologies in RT do not Require Randomised Clinical Trials" on Monday, 30 September from 17:00 18:00 in Hall 3.2.

General Sessions

J. Bogaerts, EORTC Methodology Vice Director, will present "Statistical considerations in the evaluation of biomarkers" during the FLIMS Alumni Club Workshop on Monday, 30 September 2013 at 11:35 in Room E107.

Oral Poster Presentations

Philip Poortmans, Henk Struikmans, Carine Kirkove, Volker Budach, Philippe Maingon, Maria Carla Valli, Sandra Collette, Alain Fourquet, Harry Bartelink, Walter Van den Bogaert. Irradiation of the internal mammary and medial supraclavicular lymph nodes in stage I to III breast cancer: 10 years results of the EORTC Radiation Oncology and Breast Cancer Groups phase III trial 22922/10925. Presented as a Best Abstract during the Presidential Session I on Saturday, 28 September 2013 at 14:25 in Hall 7.1.

M. Donker, E.J.T. Rutgers, C.J.H. van de Velde, R.E. Mansel, A.H. Westenberg, L. Orzalesi, L. Slaets, J. Bogaerts, G. van Tienhoven. Axillary lymph node dissection versus axillary radiotherapy: A detailed analysis of morbidity. Results from the EORTC 10981-22023 AMAROS trial. Presented as a Late Breaking Abstract during the Breast Cancer - Early Disease Proffered Papers Session on Sunday, 29 September 2013 at 10:57 in Hall 7.1

X. Paoletti, C. Le Tourneau, L Collette, E Rizzo, D. Lacombe, D Olmos, L Siu, Y Percy, L. Seymour, S.B. Kaye, J Verweij, C Massard, S. Postel-Vinay, J. Soria. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of non-cytotoxic agents. Presented as a Late Breaking Abstract during Presidential Session III on Monday, 29 September 2013 at 12:30 in Hall 7.1

H-J. Schmoll, K. Haustermans, T. Price, B. Nordlinger, R.D. Hofheinz, J-F. Daisne, J. Janssens, P. Schmidt, H. Reinel, E. Van Cutsem. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer: Response to the local treatment after chemoradiation and surgery as secondary endpoint. Presented during the "Gastrointestinal Malignancies - Colorectal Cancer I" Proffered Papers Session on Saturday, 28 September 2013 from 11:15 14:05 in RAI Auditorium.

Poster Discussion Session and Poster Session

E. Zikos, I. Ghislain, D. E. Ediebah, C. Quinten, J. van Meerbeeck, R. Stupp, M. Koller, H. Flechtner, M.A.G. Sprangers and A. Bottomley. Health-Related Quality of Life in Small-Cell Lung Cancer: A Systematic Review on Reporting of Methodological and Clinical Issues in Randomized Controlled Trials. Presented during the Symptom Science Poster Discussion session on Monday, 30 September at 12:10 in Room G106, and during the "Symptom Science" Poster Session on Monday, 30 September from 9:30 12:00 in Hall 4.

Poster Sessions

D.E. Ediebah, J.C. Reijneveld , M.J.B. Taphoorn, C. Coens, E. Zikos, A. Bottomley, M. Klein on behalf of the VU University Medical Center, EORTC Quality of Life Department and Patient Reported Outcome and Behavioral Evidence (PROBE). Patient-proxy agreement of health-related quality of life (HRQOL) measurements in low-grade glioma patients. Presented during the "Symptom Science" Poster Session on Monday, 30 September from 9:30 12:00 in Hall 4.

Rutgers E, Piccart-Gebhart MJ, Bogaerts J, Delaloge S, Van 't Veer LJ, Rubio IT, Viale G, Nitz U, Pierga JY, Vindevoghel A, Brain E, Ravdin PM, Messina C, Cardoso F on behalf of the MINDACT TRANSBIG studygroup. Baseline results of the EORTC 10041/MINDACT TRIAL (Microarray In Node 0-3 positive Disease may Avoid ChemoTherapy). Presented during the "Breast Cancer Early Disease" Poster Session on Monday 30 September 2013 from 14:00 16:30 in Hall 4.

F. Duffaud, S. Sleijfer, S. Litire, I Ray-Coquard, A Le Cesne, S Papai, I Judson, R. Hodge, S Marreaud, W. Van der Graaf. Hypertension (HTN) as a biomarker of efficacy in pazopanib-treated patients (pts) with advanced non-adipocytic soft tissue sarcoma (STS). Presented during the "Sarcoma: Soft Tissue and Bone" Poster Session on Monday, 30 September 2013 from 09:30 12:00 in Hall 4.

Collette S., Liu Y., Collette L. Opportunities and pitfalls in developing imaging biomarkers (IB) in oncology clinical trials. Presented during the "Expression Profiling" Poster Session on Saturday, 28 September 2013 from 14:00 16:30 in Hall 4.

A. Doussau, R. Thiebaut, B. Geoerger, M.C. Le Deley, P. Schffski, A. Floquet, S. Mathoulin-Plissier, E. Rizzo, P. Fumoleau, X. Paoletti. A new approach to integrate the grade of toxicity and later cycles in the analysis and reporting of phase I dose finding trials. Presented during the "Drug Development Angiogenic Inhibitors" Poster Session on Sunday, 29 September 2013 from 9:30 12:00 in Hall 4.

Xavier Paoletti, Jaap Verwej, Jean-Charles Soria, Sophie Postel Vinay, Denis Lacombe, David Olmos, Christophe Massard, Percy Ivy, Lesley Seymour, Laurence Collette, Christophe Le Tourneau. Defining dose limiting toxicity (DLT) for phase I testing molecularly targeted agents: results of an international survey. Presented during the "Regulatory/ Trial Methodology/ Pharmacy" Poster Session on Saturday, 28 September 2013 from 14:00 16:30 in Hall 4.

C. Juli, E. Tanis, B. Nordlinger, M. Mauer, A. Roth. Comparison between different scoring systems for pathological response in relation with clinical assessment in the EORTC liver metastases intergroup randomized phase III study 40983. Presented during the "Gastrointestinal Malignancies Colorectal Cancer" Poster Session on Sunday, 29 September 2013 from 14:00 16:30 in Hall 4.

Charalambous H, Pallis A, Hasan B, O'Brien MER. Attitudes and referral patterns of lung cancer specialists in Europe to specialized palliative care (SPC) and the practice of early palliative care (EPC). Presented during the "Symptom Science" Poster Session on Monday, 30 September 2013 from 9:30 12:00 in Hall 4.


'/>"/>

Contact: John Bean
john.bean@eortc.be
European Organisation for Research and Treatment of Cancer
Source:Eurekalert

Related medicine news :

1. Media alert: 24th EORTC - NCI - AACR Symposium Molecular Targets and Cancer Therapeutics
2. EORTC led intergroup trial investigates Imatinib failure-free survival in patients with GIST
3. EORTC study identifies patients with anaplastic oligodendroglioma that benefit from adjuvant PCV
4. Markers in Cancer, a joint meeting by ASCO, EORTC & NCI, 7-9 Nov 2013 (diagnostic tutorial on 5-7)
5. EORTC study shows radiotherapy and surgery provide regional control for breast cancer patients
6. EORTC BOS 2 trial opens for patients with resectable liver metastases from colorectal cancer
7. EORTC intergroup trial opens for patients with resected head of pancreas adenocarcinoma
8. EORTC study opens for elderly patients with HER-2 positive metastatic breast cancer
9. Moderate dose radiotherapy effective in EORTC trial for patients with desmoid-type fibromatosis
10. Targeted therapeutics for colon cancer to be presented at AACR meeting
11. Presidential keynote address and new research highlights from the American Society of Pediatric Otolaryngology meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
Breaking Medicine Technology: